Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
182 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Allergic Asthma - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Allergic Asthma - Pipeline Review, H1 2016', provides an overview of the Allergic Asthma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Allergic Asthma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Asthma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Asthma - The report reviews pipeline therapeutics for Allergic Asthma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Allergic Asthma therapeutics and enlists all their major and minor projects - The report assesses Allergic Asthma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Allergic Asthma Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Allergic Asthma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Allergic Asthma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Allergic Asthma Overview 8 Therapeutics Development 9 Pipeline Products for Allergic Asthma - Overview 9 Pipeline Products for Allergic Asthma - Comparative Analysis 10 Allergic Asthma - Therapeutics under Development by Companies 11 Allergic Asthma - Therapeutics under Investigation by Universities/Institutes 13 Allergic Asthma - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Allergic Asthma - Products under Development by Companies 17 Allergic Asthma - Products under Investigation by Universities/Institutes 20 Allergic Asthma - Companies Involved in Therapeutics Development 21 ALK-Abello A/S 21 Allergopharma GmbH & Co. KG 22 Amgen Inc. 23 Aquinox Pharmaceuticals Inc. 24 ASIT biotech s.a. 25 Aslan Pharmaceuticals Pte. Ltd. 26 Axikin Pharmaceuticals, Inc. 27 Baxalta Incorporated 28 Chiesi Farmaceutici SpA 29 Circassia Pharmaceuticals Plc 30 CSL Limited 31 Fountain Biopharma Inc. 32 GlaxoSmithKline Plc 33 Hydra Biosciences, Inc. 34 Infinity Pharmaceuticals, Inc. 35 Kineta, Inc. 36 Mabtech Limited 37 Marinomed Biotechnologie GmbH 38 Mycenax Biotech Inc. 39 NeoPharm Co., Ltd. 40 Oxagen Limited 41 Panacea Biotec Limited 42 Peptinnovate Limited 43 Pharmaxis Limited 44 Protectimmun GmbH 45 Stallergenes SAS 46 sterna biologicals Gmbh & Co KG 47 Swecure AB 48 The International Biotechnology Center (IBC) Generium 49 Verona Pharma Plc 50 Allergic Asthma - Therapeutics Assessment 51 Assessment by Monotherapy Products 51 Assessment by Combination Products 52 Assessment by Target 53 Assessment by Mechanism of Action 56 Assessment by Route of Administration 59 Assessment by Molecule Type 61 Drug Profiles 63 AcTMP-1 - Drug Profile 63 AMG-282 - Drug Profile 64 AQX-1125 - Drug Profile 65 Arabinogalactan - Drug Profile 68 ASLAN-004 - Drug Profile 69 ASM-8 - Drug Profile 70 AXP-1275 - Drug Profile 72 beta-escin - Drug Profile 73 CHF-6001 - Drug Profile 74 CSL-311 - Drug Profile 76 dalazatide - Drug Profile 77 Drug to Inhibit PI3 Kinase Delta for Asthma - Drug Profile 79 duvelisib - Drug Profile 80 EP-67 - Drug Profile 83 FB-825 - Drug Profile 84 GNR-044 - Drug Profile 85 GSK-2245035 - Drug Profile 86 hdm-ASIT - Drug Profile 88 HX-100 - Drug Profile 89 Lactococcus lactis G121 - Drug Profile 91 Leukothera - Drug Profile 92 OC-000459 - Drug Profile 94 OC-2417 - Drug Profile 96 omalizumab biosimilar - Drug Profile 97 omalizumab biosimilar - Drug Profile 98 omalizumab biosimilar - Drug Profile 99 omalizumab biosimilar - Drug Profile 100 omalizumab biosimilar - Drug Profile 101 omalizumab biosimilar - Drug Profile 102 OND-86 - Drug Profile 103 pemirolast potassium - Drug Profile 104 pentosan polysulfate sodium - Drug Profile 105 PIN-201601 - Drug Profile 106 RPL-554 - Drug Profile 107 S-1226 - Drug Profile 110 SB-010 - Drug Profile 112 SG-100 - Drug Profile 114 SM-301 - Drug Profile 115 Small Molecule for Allergic Asthma - Drug Profile 116 Small Molecules for Allergic Asthma - Drug Profile 117 Small Molecules to Inhibit CaMKII for Allergic Asthma - Drug Profile 118 standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile 119 standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile 121 standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract - Drug Profile 123 SWE-01 - Drug Profile 125 tezepelumab - Drug Profile 126 Vaccine for Allergic Rhinitis and Allergic Asthma - Drug Profile 128 Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma - Drug Profile 129 Allergic Asthma - Recent Pipeline Updates 130 Allergic Asthma - Dormant Projects 164 Allergic Asthma - Discontinued Products 168 Allergic Asthma - Product Development Milestones 169 Featured News & Press Releases 169 Appendix 177 Methodology 177 Coverage 177 Secondary Research 177 Primary Research 177 Expert Panel Validation 177 Contact Us 177 Disclaimer 178
List of Tables Number of Products under Development for Allergic Asthma, H1 2016 13 Number of Products under Development for Allergic Asthma - Comparative Analysis, H1 2016 14 Number of Products under Development by Companies, H1 2016 15 Number of Products under Development by Companies, H1 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H1 2016 17 Comparative Analysis by Late Stage Development, H1 2016 18 Comparative Analysis by Clinical Stage Development, H1 2016 19 Comparative Analysis by Early Stage Development, H1 2016 20 Products under Development by Companies, H1 2016 21 Products under Development by Companies, H1 2016 (Contd..1) 22 Products under Development by Companies, H1 2016 (Contd..2) 23 Products under Investigation by Universities/Institutes, H1 2016 24 Allergic Asthma - Pipeline by ALK-Abello A/S, H1 2016 25 Allergic Asthma - Pipeline by Allergopharma GmbH & Co. KG, H1 2016 26 Allergic Asthma - Pipeline by Amgen Inc., H1 2016 27 Allergic Asthma - Pipeline by Aquinox Pharmaceuticals Inc., H1 2016 28 Allergic Asthma - Pipeline by ASIT biotech s.a., H1 2016 29 Allergic Asthma - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2016 30 Allergic Asthma - Pipeline by Axikin Pharmaceuticals, Inc., H1 2016 31 Allergic Asthma - Pipeline by Baxalta Incorporated, H1 2016 32 Allergic Asthma - Pipeline by Chiesi Farmaceutici SpA, H1 2016 33 Allergic Asthma - Pipeline by Circassia Pharmaceuticals Plc, H1 2016 34 Allergic Asthma - Pipeline by CSL Limited, H1 2016 35 Allergic Asthma - Pipeline by Fountain Biopharma Inc., H1 2016 36 Allergic Asthma - Pipeline by GlaxoSmithKline Plc, H1 2016 37 Allergic Asthma - Pipeline by Hydra Biosciences, Inc., H1 2016 38 Allergic Asthma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 39 Allergic Asthma - Pipeline by Kineta, Inc., H1 2016 40 Allergic Asthma - Pipeline by Mabtech Limited, H1 2016 41 Allergic Asthma - Pipeline by Marinomed Biotechnologie GmbH, H1 2016 42 Allergic Asthma - Pipeline by Mycenax Biotech Inc., H1 2016 43 Allergic Asthma - Pipeline by NeoPharm Co., Ltd., H1 2016 44 Allergic Asthma - Pipeline by Oxagen Limited, H1 2016 45 Allergic Asthma - Pipeline by Panacea Biotec Limited, H1 2016 46 Allergic Asthma - Pipeline by Peptinnovate Limited, H1 2016 47 Allergic Asthma - Pipeline by Pharmaxis Limited, H1 2016 48 Allergic Asthma - Pipeline by Protectimmun GmbH, H1 2016 49 Allergic Asthma - Pipeline by Stallergenes SAS, H1 2016 50 Allergic Asthma - Pipeline by sterna biologicals Gmbh & Co KG, H1 2016 51 Allergic Asthma - Pipeline by Swecure AB, H1 2016 52 Allergic Asthma - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016 53 Allergic Asthma - Pipeline by Verona Pharma Plc, H1 2016 54 Assessment by Monotherapy Products, H1 2016 55 Assessment by Combination Products, H1 2016 56 Number of Products by Stage and Target, H1 2016 58 Number of Products by Stage and Mechanism of Action, H1 2016 61 Number of Products by Stage and Route of Administration, H1 2016 64 Number of Products by Stage and Molecule Type, H1 2016 66 Allergic Asthma Therapeutics - Recent Pipeline Updates, H1 2016 134 Allergic Asthma - Dormant Projects, H1 2016 168 Allergic Asthma - Dormant Projects (Contd..1), H1 2016 169 Allergic Asthma - Dormant Projects (Contd..2), H1 2016 170 Allergic Asthma - Dormant Projects (Contd..3), H1 2016 171 Allergic Asthma - Discontinued Products, H1 2016 172
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.